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Abstract
Objective
Multiplex gastrointestinal pathogen panel (GPP) tests simultaneously identify bacterial, viral
and parasitic pathogens from the stool samples of patients with suspected infectious gastro-
enteritis presenting in hospital or the community. We undertook a systematic review to com-
pare the accuracy of GPP tests with standard microbiology techniques.
Review methods
Searches in Medline, Embase, Web of Science and the Cochrane library were undertaken
from inception to January 2016. Eligible studies compared GPP tests with standard microbi-
ology techniques in patients with suspected gastroenteritis. Quality assessment of included
studies used tailored QUADAS-2. In the absence of a reference standard we analysed test
performance taking GPP tests and standard microbiology techniques in turn as the bench-
mark test, using random effects meta-analysis of proportions.
Results
No study provided an adequate reference standard with which to compare the test accuracy
of GPP and conventional tests. Ten studies informed a meta-analysis of positive and nega-
tive agreement. Positive agreement across all pathogens was 0.93 (95% CI 0.90 to 0.96)
when conventional methods were the benchmark and 0.68 (95% CI: 0.58 to 0.77) when
GPP provided the benchmark. Negative agreement was high in both instances due to the
high proportion of negative cases. GPP testing produced a greater number of pathogen-
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positive findings than conventional testing. It is unclear whether these additional ‘positives’
are clinically important.
Conclusions
GPP testing has the potential to simplify testing and accelerate reporting when compared to
conventional microbiology methods. However the impact of GPP testing upon the manage-
ment, treatment and outcome of patients is poorly understood and further studies are
needed to evaluate the health economic impact of GPP testing compared with standard
methods.
The review protocol is registered with PROSPERO as CRD42016033320.
Introduction
Gastroenteritis is a common, transient, mostly self-limiting disorder usually caused by infec-
tion with viruses, bacteria or parasites. Identifying the infectious agent in severe cases may aid
decision making in terms of treatment, isolation, management, and further investigations.
Standard laboratory methods include culture for bacteria, nucleic acid amplification and
immunoassays for viruses and microscopy or enzyme immunoassays for parasites as well as
culture for amoeba. Tests have turnaround times of up to three days and in practice recom-
mendations for routine screening of stool samples for people with diarrhoea, vomiting and
abdominal pain are for a limited range of pathogens in line with the Public Health England
syndromic algorithm [1] although the number of pathogens actually tested for varies. The
algorithm prescribes testing in two stages aiming to rule out common gastrointestinal patho-
gens. The number and type of pathogens tested for depends on the setting (hospital versus
community), season, as well as whether patients are children or travellers [1]. Gastrointestinal
pathogen panel (GPP) tests offer a more extensive range of pathogens than is covered by the
algorithm with some variation between panels. GPP tests exploit multiplex nucleic acid ampli-
fication methodology, testing for a wide range of bacteria, viruses and parasites in a single run,
potentially increasing the throughput and volume of information from one test run and
decreasing reporting times to a day or less. Systems differ considerably in the number of sam-
ples that can be run simultaneously.
Adequate evaluation of GPP tests is important as the tests gradually diffuse into routine
clinical practice. Normally, a reference method is selected that identifies the true infectious
cause and provides a standard with which to assess alternative tests, assessing their test sensi-
tivity and specificity. Ideally such a reference standard is incontrovertibly accurate and inde-
pendent. However neither GPP nor conventional testing can be assumed to have greater
accuracy in identifying clinically important pathology, and no further test has been identified
to act as an independent reference standard. Polymerase chain reaction (PCR) can detect path-
ogen DNA at very low levels including from non-viable organisms, generally leading to more
test positive outcomes, but of uncertain clinical importance. In the absence of a reference stan-
dard, or an adequate resolving test for discrepant analysis, sensitivity and specificity cannot be
calculated [2].
In such circumstances the Food and Drug Administration (FDA) recommends reporting
measures of positive and negative test agreement without further validation of discordant or
concordant test results in the Statistical Guidance on Reporting Results from Studies Evaluating
Diagnostic Tests [3] while the Quality Assessment of Diagnostic Accuracy Studies (QUADAS
Test performance of gastrointestinal panel tests
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2) tool [4] classifies primary studies of test accuracy as being at high risk of bias when an inade-
quate reference standard is used. While currently available evidence on test accuracy limits the
interpretation of results and usefulness to decision makers, exploring test agreement by taking
each of the tests in turn as the benchmark test (rather than reference standard) can highlight dif-
ferences between the tests. A systematic review of the clinical effectiveness of GPP testing when
compared to standard microbiology laboratory methods was undertaken in support of decision
making about the adoption of GPP testing in patients with symptoms suggestive of infectious
gastroenteritis presenting at a community or hospital setting.
Methods
This review forms part of a broader Health Technology Assessment (HTA) report by the same
authors.
Search strategy
Multiple electronic database searches were undertaken by a qualified information specialist from
inception to January 2016 including searches in Medline, Embase, Web of Science and Cochrane
Database of Systematic Reviews with supplementary searches of other online resources. The
search combined subject headings and free text words including terms for gastroenteritis and
multiplex polymerase chain reaction. Full searches are available in S1 File. Reference lists of all
reviews and included studies were screened and trial websites were searched for ongoing studies.
Authors were contacted to seek clarification on study populations when necessary.
Study eligibility criteria
Studies of adults and children with suspected gastroenteritis comparing GPP tests with com-
prehensive coverage of bacteria, viruses and parasites with standard microbiology techniques
reporting test performance, patient management, clinical and patient reported outcomes were
included. The setting considered was clinical laboratories receiving samples from primary and
secondary care. Eligible study designs followed a hierarchy of best available evidence with the
most desirable being 1) test-treat trials comparing clinically relevant outcomes (e.g., morbidity,
mortality, length of stay and length of isolation) for patients randomised to either conventional
testing or GPP. This was followed by 2) clinical diagnostic test accuracy studies that compare
the index tests (GPP) and the comparator (standard microbiology methods) to an adequate
reference standard, 3) studies that compare discrepant results between the index tests (GPP)
and the comparator (standard microbiology methods) using an unbiased umpire test [2], 4)
studies of agreement and disagreement between the index tests (GPP) and the comparator
without using an unbiased umpire test and 5) studies of head to head comparisons of different
index tests (GPP) reporting agreement of tests. Only studies that reported sufficient raw data
to calculate positive and negative agreement by pathogen were considered.
Studies were excluded if they considered partial tests with coverage of less than the three
groups of pathogens and if no positive and negative agreement by pathogen could be deter-
mined. Additionally, reviews, biological studies, case reports, editorials and opinions, poster
presentations without supporting abstracts, non-English language reports, and meeting
abstracts without sufficient numerical detail on test performance per pathogen were excluded.
Study selection
Two reviewers independently screened the titles and abstracts of all records identified by the
searches. Full texts of all studies deemed potentially relevant were obtained and two reviewers
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independently assessed these for inclusion. Discrepancies at both stages were resolved through
discussion.
Data extraction
Test results for GPP and standard microbiology methods were extracted at the pathogen level
into two-by-two contingency tables following the format in Table 1.
Assessment of risk of bias and applicability
Quality assessment of included studies was undertaken by two independent reviewers and
used tailored QUADAS-2 [4]. Quality assessment assessed the risk of bias and applicability
concerns for included studies at the pathogen level where the GPP method was the index test,
conventional methods were the comparator and any efforts to verify discordant results were
assessed under the reference standard domain. The main adaptation of the QUADAS-2 tool
consisted of the addition of a domain for the comparator. The eligible studies compared GPP
testing to a comparator which consisted broadly speaking of a range of standard microbiology
tests which cannot be classed as the reference standard because GPP testing may be superior to
standard microbiology methods. Therefore, the comparator was assessed in addition to the
index test and the reference standard. Similar signalling questions in terms of blinding and
threshold as for the index test were considered for the comparator. Furthermore, we added sig-
nalling questions to the ‘reference standard’ as well as the ‘flow and timing’ domain requiring
for a low risk of bias judgment, that the verification methods used in the studies were indepen-
dent and unbiased, all discordant results rather than a proportion had received verification
and that all samples had received the comparator methods for all pathogens considered in the
study.
Data synthesis
In the absence of a reference standard we calculated positive agreement (a/a+c) and negative
agreement (d/b+d) when benchmarked against the comparator (mainly standard microbiol-
ogy methods) and positive agreement (a/a+b) and negative agreement (d/c+d) when bench-
marked against GPP for each pathogen using methods outlined in the Statistical Guidance on
Reporting Results from Studies Evaluating Diagnostic Tests by the FDA [3]. This is equivalent
to measuring the sensitivity and specificity of GPP using standard microbiology methods as
the reference standard, and the sensitivity and specificity of standard microbiology methods
using GPP as the reference standard. Positive and negative agreements, using the two bench-
marks, were then meta-analysed by pathogen if the denominator was20 using random
effects meta-analysis of proportions using the metaprop command in Stata SE 14.1 [5] and
reported in tables and Forest plots. Methods for bivariate analysis of diagnostic tests findings
were not used because of restrictive requirements for the number of studies within each patho-
gen (minimum of 4 studies with complete data). Exact binomial methods were used to esti-
mate 95% confidence intervals using the Freeman-Tukey transformation of proportions, and
the I2 statistic of between study heterogeneity was computed. Data verifying discordant results
was tabulated to explore the option of discrepant analysis using a suitable resolving test [6].
Table 1. Contingency table of test agreement.
Comparator + Comparator -
GPP + a) +/+ b) -/+
GPP - c) +/- d) -/-
doi:10.1371/journal.pone.0173196.t001
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Results
The search identified 3468 records. Following duplicate removal, we screened 2215 unique
records of which 110 were taken forward to full text assessment. Ten studies contributed suffi-
cient data to calculate positive and negative agreement and be included in the meta-analysis
[7–16]. The PRISMA diagram of study selection is provided in Fig 1.
Fig 1. PRISMA flow diagram of study selection.
doi:10.1371/journal.pone.0173196.g001
Test performance of gastrointestinal panel tests
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Study characteristics
Included studies only represented study designs 4 and 5 described in the methods section.
Studies were heterogeneous in terms of participants included (hospital versus community,
risk, comorbidities), country of origin (developing versus developed), standard microbiology
methods used and number and type of pathogens considered (see S1 Table for study character-
istics). Of the 10 studies eight evaluated the xTAG GPP test, one study evaluated the FilmArray
GPP test and a further study evaluated both tests.
Risk of bias and concerns regarding applicability of study findings
The risk of bias of the included studies of test accuracy was generally high (S2 Table). None of
the studies used a reference standard against which the GPP tests and standard microbiology
methods could be reliably evaluated. Instead, in most studies, the GPP tests were compared
against the standard microbiology methods, biasing the assessment. Discrepant results
between GPP test and standard microbiology methods were verified at the pathogen level in 4/
10 studies, although confirmatory tests were not adequately independent of GPP and/or stan-
dard microbiology tests. In many cases, the standard microbiology methods were not per-
formed for all pathogens covered by the GPP test. There were concerns about the applicability
and relevance of standard microbiology methods and verification tests used in the majority of
studies, in reference to routine clinical practice.
Test performance
Pooled estimates of positive and negative agreement by pathogen and overall for all pathogens
between GPP and standard microbiology methods are given in Table 2 (standard microbiology
methods provide the benchmark) and Table 3 (GPP test provides the benchmark). Contin-
gency tables of the raw data of test agreement by pathogen informing the meta-analysis are
provided in S3 Table. Overall, more studies contributed to the calculation of negative than pos-
itive agreement as only studies with sufficient numbers (denominator20) were included in
the analysis and the presence of pathogens was a rare event. For a number of pathogens, E. coli
O157, ETEC,STEC, Vibrio cholera, Yersinia enterocolitica and Entamoeba histolytica (rare
pathogens or no test requested by physician and marked as empty rows in the Tables 2 and 3)
limited data were available and no positive agreement could be estimated.
Standard microbiology methods providing the benchmark. Meta-analysis showed that
when standard microbiology methods provided the benchmark, virtually all positive cases
found by xTAG were confirmed by conventional testing leading to high levels of positive
agreement findings (0.93 [95% CI 0.90 to 0.96]) (Table 2). Additional positives identified by
xTAG were few compared to the vast majority of specimens that are pathogen-negative, thus
negative agreement remained high (0.98 [95% CI 0.98 to 0.99]). Although overall findings
were indicative, they nonetheless feature an equal weighting of pathogen-level findings not
reflecting the prevalence of individual pathogens.
There was generally little variation between pathogens for both positive and negative agree-
ment. Positive agreement for adenovirus was an exception where positive agreement was con-
siderably lower at 0.56. This is visualised in the Forest plot in Fig 2. Gu et al. 2015 [13]
reported that an additional 20 samples positive for adenovirus detected by comparator were
due to the use of multiplex PCR, which detected all serotypes while xTAG only detected ade-
novirus 40/41 resulting in the poor agreement of tests for this virus. The outlying finding for
Salmonella (Pankhurst et al., 2014 [16]), caused by a high number of missed Salmonella infec-
tions by xTAG, could not be explained.
Test performance of gastrointestinal panel tests
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Generally, both tests agreed about the absence of pathogens, masking the relatively small
number of disagreements. The Forest plot shows, however, that there were a few outliers
where studies report a significantly higher number of positives for certain pathogens with
xTAG compared to standard microbiology methods, specifically Campylobacter and norovirus
in a small study of 49 adult kidney transplant recipients [9] and Salmonella in a study where
bacteria were tested by PCR as well as culture.[11] (Figure A in S1 Figs)
Used as a measure of overall heterogeneity of estimates, I2 is moderate (for positive agree-
ment) to high (for negative agreement) at the pathogen level.
Table 2. Positive and negative agreement: xTAG vs. standard microbiology methods (benchmark).
Positive Agreement: RE LCI UCI N Q p I2
C. difficile 0.959 0.933 0.980 5 5.9 0.207 32%
Campylobacter 0.959 0.924 0.985 6 8.0 0.157 37%
E. coli O157 - - - - - - -
ETEC - - - - - - -
STEC - - - - - - -
Salmonella 0.818 0.666 0.934 5 30.8 0.000 87%
Shigella 0.989 0.949 1.000 3 3.6 0.164 45%
Vibrio cholerae - - - - - - -
Yersinia enterocolitica - - - - - - -
Adenovirus 0.558 0.413 0.699 - - - -
Norovirus 0.927 0.893 0.956 7 10.9 0.093 45%
Rotavirus 0.958 0.920 0.985 3 2.9 0.240 30%
Cryptosporidium 0.914 0.794 0.989 1 - - -
Entamoeba histolytica - - - - - - -
Giardia 1.000 0.935 1.000 1 - - -
Negative Agreement: RE LCI UCI N Q p I2
C. difficile 0.968 0.933 0.991 7 128.0 0.000 95%
Campylobacter 0.968 0.950 0.982 10 83.7 0.000 89%
E. coli O157 0.995 0.990 0.998 6 10.8 0.055 54%
ETEC 0.988 0.964 1.000 4 23.7 0.000 87%
STEC 0.990 0.984 0.995 4 2.8 0.418 0%
Salmonella 0.940 0.866 0.986 10 726.0 0.000 99%
Shigella 0.985 0.965 0.997 8 120.0 0.000 94%
Vibrio cholerae 1.000 0.998 1.000 4 0.1 0.988 0%
Yersinia enterocolitica 1.000 1.000 1.000 4 0.4 0.933 0%
Adenovirus 0.990 0.983 0.996 2 -
Norovirus 0.969 0.944 0.987 12 239.0 0.000 95%
Rotavirus 0.991 0.979 0.999 8 36.7 0.000 81%
Cryptosporidium 0.989 0.954 1.000 5 77.4 0.000 95%
Entamoeba histolytica 0.991 0.979 0.998 5 20.5 0.000 81%
Giardia 0.989 0.970 0.999 7 46.4 0.000 87%
Overall Agreement: RE LCI UCI N Q p I2
Positive 0.929 0.898 0.955 33 188.3 0.000 83%
Negative 0.982 0.976 0.988 101 2080.8 0.000 95%
RE: Random effect estimate, measure of agreement; LCI: lower confidence interval; UCI: upper confidence interval; N: number of studies contributing; Q, p,
I2: Heterogeneity Cochrane Q statistic, p-value and I2 index
doi:10.1371/journal.pone.0173196.t002
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In summary, using standard microbiology methods as benchmark the impression was that
GPP testing and standard microbiology methods provide very similar results.
GPP testing providing the benchmark. Levels of agreement when xTAG provided the
benchmark are shown in Table 3.The positive agreement between xTAG and conventional
methods was considerably reduced when xTAG provided the benchmark. The Forest plot in
Fig 3 visualises the inconsistency and variation in positive agreement between studies across
all pathogens. When xTAG was the benchmark, the positive cases ‘missed’ by standard micro-
biology methods had a considerable impact on the positive agreement findings.
Table 3. Positive and negative agreement: Standard microbiology methods vs. xTAG (Benchmark).
Positive Agreement: RE LCI UCI N Q p I2
C. difficile 0.801 0.594 0.948 5 124.0 0.000 97%
Campylobacter 0.639 0.398 0.849 7 167.0 0.000 96%
E. coli O157 0.750 0.534 0.920 1 - - -
ETEC - - - - - - -
STEC - - - - - - -
Salmonella 0.484 0.278 0.693 8 173.0 0.000 96%
Shigella 0.734 0.381 0.971 3 61.6 0.000 97%
Vibrio cholerae - - - - - - -
Yersinia enterocolitica - - - - - - -
Adenovirus 0.570 0.425 0.710 2 - - -
Norovirus 0.774 0.584 0.920 8 215.0 0.000 97%
Rotavirus 0.924 0.853 0.975 3 6.5 0.039 69%
Cryptosporidium 0.508 0.407 0.608 2 - - -
Entamoeba histolytica - - - - - - -
Giardia 0.337 0.237 0.444 2 - - -
Negative Agreement: RE LCI UCI N Q p I2
C. difficile 0.996 0.992 0.999 7 11.1 0.084 46%
Campylobacter 0.998 0.994 1.000 10 37.4 0.000 76%
E. coli O157 1.000 1.000 1.000 6 3.4 0.637 0%
ETEC 0.999 0.996 1.000 4 3.0 0.393 0%
STEC 1.000 0.998 1.000 4 4.9 0.182 38%
Salmonella 0.992 0.980 0.999 10 94.4 0.000 91%
Shigella 1.000 0.999 1.000 8 12.0 0.099 42%
Vibrio cholerae 1.000 0.999 1.000 4 3.5 0.326 13%
Yersinia enterocolitica 1.000 0.999 1.000 4 0.4 0.933 0%
Astrovirus 0.989 0.971 0.999 7 68.7 0.000 91%
Norovirus 0.995 0.990 0.998 12 34.9 0.000 69%
Rotavirus 0.998 0.992 1.000 8 29.3 0.000 76%
Cryptosporidium 1.000 0.999 1.000 5 2.0 0.743 0%
Entamoeba histolytica 1.000 0.999 1.000 5 3.5 0.481 0%
Giardia 1.000 1.000 1.000 7 1.8 0.941 0%
Overall Agreement RE LCI UCI N Q p I2
Positive 0.678 0.580 0.770 41 1340.5 0.000 97%
Negative 0.998 0.997 0.999 101 429.2 0.000 77%
RE: Random effect estimate, measure of agreement; LCI: lower confidence interval; UCI: upper confidence interval; N: number of studies contributing; Q, p,
I2: Heterogeneity Cochrane Q statistic, p-value and I2 index
doi:10.1371/journal.pone.0173196.t003
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Since the overall positive agreement is 0.68 (95% CI: 0.58 to 0.77), inverting these figures
means that xTAG finds about 1.5 times more positive results (95% CI: 1.3 to 1.7). Negative
agreement was consistently very high across studies and pathogens (Figure B in S1 Figs) with
the exception of the Gu et al. (2015) study [13] discussed previously. Heterogeneity was mod-
erate to high when considering I2 and was higher for positive agreement than for negative
agreement. Using the GPP test as the benchmark, it becomes clear GPP testing detects signifi-
cantly more pathogens.
Only two studies [7 13] contributed data to the meta-analytic evaluation of the FilmArray
GPP test with detailed outcomes reported in a recent HTA report by the same authors. Quali-
tatively these findings were similar to the findings reported here for the xTAG GPP test.
Verification of discordant results
In the absence of a reference standard to verify test results, four studies [7 10 12 16] verified
discordant pathogen findings by pathogen that did not agree when tested by GPP and conven-
tional methods (S4 Table). Verification methods were PCR based. Even though verification
methods differed from standard microbiology methods and used different molecular targets
when compared to GPP assays, they could not be considered independent. GPP assays essen-
tially use PCR and other PCR-based methods would be expected to resolve discordant results
in their favour. A further complexity was that sometimes conventional methods included
some use of PCR. Discordant analysis of GPP positive/ standard microbiology methods nega-
tive generally favoured GPP as anticipated, however analysis of GPP negative/ standard micro-
biology method outcomes more often favoured standard microbiology methods (S4 Table).
Discordant analysis failed to resolve all discordant samples; for a considerable number of dis-
cordant results, discrepant analysis did not help to identify the underlying cause of the discrep-
ancy. No particular pattern for any specific pathogen emerged from the discordant analyses.
Discussion
Principal study findings
Our meta-analysis of ten primary studies comparing GPP testing with standard microbiology
methods reports the range of possible outcomes of positive agreement when each method in
turn was considered the benchmark. Positive agreement ranged from 0.93 (95% CI 0.90 to
0.96) when conventional methods provided the benchmark to 0.68 (95% CI: 0.58 to 0.77)
when GPP provided the benchmark while negative agreement was consistently high. This was
due to the large number of negative results agreed upon by both methods. No previous systematic
review of GPP tests was identified in our review, but assuming the use of conventional testing as
a reference standard would mask issues with the use of GPP tests. In particular, gastrointestinal
pathogen panel tests generate significantly more additional positive results. These, however, are
of uncertain clinical importance in the absence of an appropriate reference standard or a suitable
resolver test for discrepant analysis. On the other hand high positive agreement when conven-
tional methods provided the benchmark could not be consistently shown by all studies for all
pathogens suggesting that GPP performance differs for different pathogens. Pankhurst et al.
(2014) [16] reported a great number of additional positives with conventional laboratory methods
for Salmonella spp. which were missed with molecular based tests. Poor detection of some patho-
gens in some studies requires further investigation and assessment of which assays should be
reported within a GPP.
Fig 2. Positive agreement: xTAG vs. conventional testing (benchmark).
doi:10.1371/journal.pone.0173196.g002
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Strengths and weaknesses
In the absence of more robust methods of assessing test accuracy, positive and negative agree-
ments have been produced against a benchmark, as recommended by FDA guidance. [3] The
meta-analytic outcomes reported here are of exploratory nature summarising the available evi-
dence, illustrating patterns in the data and describing heterogeneity. Test agreement is not a
measure of test accuracy as it neither considers either approach as the ‘truth’ nor does it con-
sider if both tests while agreeing are actually wrong. Rather, by varying the benchmark, differ-
ent views about the level of agreement between tests are explored. Findings were typically
heterogeneous, probably reflecting in part methodological and statistical heterogeneity and
drawing from studies of variable quality. High levels of heterogeneity for negative agreement
were partly driven by variations in large and very precise study estimates. Additionally, a high
I2 was possibly caused by differences in thresholds used across studies. We report I2 as a statis-
tical measure of between study heterogeneity which is not often used in test accuracy studies
because it does not account for heterogeneity due to a threshold effect. As the studies included
a number of different standard microbiology tests and did not report thresholds it is difficult
to judge to what extent a threshold effect existed. Therefore the finding of high levels of hetero-
geneity is of interest and we have listed a number of reasons that could explain this heterogene-
ity but cannot exclude that differences in threshold caused at least some of this heterogeneity.
The presence of very small sample sizes and heterogeneity creates particular methodological
problems for meta-analyses of diagnostic test performance. A textbook approach might include
all studies (large and small) regardless of patient numbers and assess test accuracy using bivari-
ate methods. However in the present analysis, inclusion of very small studies (<20) has a dra-
matic impact upon sparsely informed random effect models. Bivariate analyses are balanced,
including studies contributing to sensitivity and specificity estimates of test accuracy. Addition-
ally available routines require a minimum of four pathogen studies to work. Use of the bivariate
approach would exclude a large number of informative negative agreement studies from the
analyses presented in this paper. Pragmatically, the greater inclusivity of univariate analysis of
agreement values was preferred to the theoretical correctness of bivariate analysis.
Analyses are presented at the pathogen level requiring independence assumptions both
within and between pathogens, i.e. repeat samples of the same patient are not included and
having one pathogen does not affect the likelihood of having another pathogen. Pooled sum-
mary estimates (across pathogens) have been included for information. However, these pooled
estimates are not weighted by the prevalence of the different pathogens, and include varying
multiple usage of samples where studies have tested samples with varying components of the
conventional panel of tests, thus violating the independence assumption. Accepting these limi-
tations and issues the summary findings remain qualitatively informative.
Within the clinical studies identified, many pathogens were present only at low prevalence,
and the context of studies included a mixture of different patient populations (e.g. children,
immunocompromised patients, community) each with their own distribution of prevalence of
pathogens. This was not considered in sensitivity analyses due to the number of potential
covariates (not always well quantified) and issues of multiplicity.
This review has evaluated GPP systems according to their current specification, but it is
anticipated the coverage of these systems will continue to evolve in response to changing path-
ogen prevalence, hence the evaluation problem is a dynamic one.
Fig 3. Positive agreement: Conventional testing vs. xTAG (Benchmark).
doi:10.1371/journal.pone.0173196.g003
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Meaning of a positive test outcome: Implications for clinicians and
policymakers
If conventional methods accurately identify clinically important disease then GPP testing
would correctly identify the same positive cases but add further false positive patients who
may receive unnecessary treatment and potentially a delayed return to normal activities. How-
ever, if GPP testing is accurate (all of its positives are clinically important) then current testing
misses clinically important pathogens, potentially resulting in under-treatment and impaired
infection control measures. Expertise is important when identifying parasites by standard
microbiology methods, where detection is dependent upon the life-cycle of the parasite and its
appearance in the inhomogeneous stool sample. These difficulties may be overcome by using
GPP testing. The consequence for clinical care is complicated since most infections are self-
limiting and require no pathogen specific treatment, just hygiene, hydration and watchful
waiting. Only for a select few pathogens is specific treatment recommended (C. difficile, some
strains of Salmonella, Shigella, E. coli (non-STEC), Campylobacter and Giardia) although not
all patients are treated. By reducing reporting from three to one days, GPP testing has the
potential to streamline the management of non-infectious cases and use of hospital isolation
rooms, intended to reduce the spread of infection. Currently there is no robust evidence to
support changes in hospital care due to GPP testing and their plausibility is uncertain. For
example, length of stay in hospital and use of isolation rooms may be primarily driven by
comorbidity and hygiene rather than identification of infectious agents.
Currently the clinical importance of the additional pathogens identified by GPP testing is
uncertain and there is concern that at least some of the additional findings are non-viable patho-
gens. GPP tests target microbial DNA and RNA. This will result in challenges associated with the
interpretation of GPP test results in clinical practice, a concern shared by other authors [17].
Firstly, GPP tests cannot distinguish between viable and non-viable pathogens. The detection of
microbial nucleic acid does not necessarily imply the presence of viable, replicating organisms
responsible for disease. Secondly, many pathogens can exist asymptomatically (e.g., norovirus
and Salmonella spp) or sub-clinically (e.g., C. difficile nontoxigenic strains) in a colonization-like
status [18–20] where association with disease is unlikely. It is believed that this in part explains
the increased number of positive results as well as the increased findings of co-infections with
GPP testing. Further understanding is needed as to how these results should be interpreted.
However the inclusiveness of panel tests may provide a gain for users, e.g. Enteroaggregative E.
coli (EAEC) is not detected by routine culture.
In addition to providing pathogen-level analysis, studies typically reported overall levels of
detection of pathogens with a GPP test compared to a battery of standard microbiology meth-
ods. Reporting the total number of pathogens detected may mislead by confounding greater
GPP ‘sensitivity’ to detect specific pathogens with different coverage of pathogens by GPP and
conventional methods. Concordance of methods depends on including a common number
and type of pathogens tested. Thus discrepancies between GPP tests and conventional meth-
ods may result not only from differences in accuracy but also from differences in their respec-
tive targets. For example, discrepancies reported by Gu et al. (2015) [13] for adenovirus may
have been due to comparator PCR identifying all adenovirus strains while the GPP system
only identified adenovirus 40 and 41. Similarly Pankhurst et al. (2014) [16] reported that
xTAG has two targets for C. difficile (genes for toxins A and B) and includes two primers
against norovirus GI and GII strains. However, the single quantitative PCRs used as compara-
tors in the study targeted only the gene for toxin B or the GII strain. This misalignment prob-
lem may be exacerbated when comparing different GPP systems with their varying coverage.
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An additional limitation of GPP tests is that although the presence of bacterial pathogens is
identified there is no bacterial culture to support either antimicrobial susceptibility testing or
subtyping to support public health surveillance. Culturing from positive samples may therefore
be required to guide antimicrobial treatment or public health investigation when these are
required.
Future research needs
Agreement measures are not measures of test performance in a conventional sense, and only
adequately designed research will resolve uncertainties about the introduction of GPP testing.
It may not be possible to design a study with an adequate independent reference standard.
Molecular methods may not be the best option to address the problem, as the presence of path-
ogen DNA may not answer the question of the clinical importance of the identified pathogens.
On the other hand there is widespread belief that conventional microbiology laboratory meth-
odologies are going to be outperformed by new PCR based technology. A randomised con-
trolled trial, randomising patients to conventional or GPP testing, would establish the relative
clinical and cost-effectiveness outcomes of the different approaches.
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